SMN1 and Duchenne muscular dystrophy: Splice-switching oligonucleotides (SSOs) have been approved by the FDA for Duchenne muscular dystrophy (DMD) and SMA, targeting the splice site to prevent the binding and assembly of the spliceosome to the target gene [127,128].